Proteon Therapeutics Inc (NASDAQ:PRTO) has been assigned an average recommendation of “Hold” from the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $3.43.
PRTO has been the topic of several analyst reports. Zacks Investment Research lowered shares of Proteon Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright restated a “hold” rating and issued a $2.30 price target on shares of Proteon Therapeutics in a research note on Wednesday, November 8th. Finally, Robert W. Baird restated a “hold” rating and issued a $2.00 price target on shares of Proteon Therapeutics in a research note on Friday, November 10th.
Proteon Therapeutics (NASDAQ:PRTO) remained flat at $$1.90 on Monday. The stock had a trading volume of 37,500 shares, compared to its average volume of 23,700. The stock has a market cap of $33.48, a price-to-earnings ratio of -0.86 and a beta of 1.62. Proteon Therapeutics has a twelve month low of $1.10 and a twelve month high of $2.75.
In related news, Director James E. Flynn acquired 110,557 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was acquired at an average cost of $1.75 per share, for a total transaction of $193,474.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders bought 122,852 shares of company stock valued at $216,533 over the last quarter. Insiders own 36.30% of the company’s stock.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC bought a new position in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up about 0.2% of RA Capital Management LLC’s holdings, making the stock its 22nd largest holding. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 50.05% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Proteon Therapeutics Inc (PRTO) PT at $3.43” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/brokerages-set-proteon-therapeutics-inc-prto-pt-at-3-43.html.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.